---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017412"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:34:33.511324+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio's MB-106 CAR-T interim data selected for ASH; complete responses in FL

## Summary
- Interim Phase 1/2 data for MB-106 (CD20-targeted CAR-T) accepted as poster at ASH Dec 9-12, 2023.
- At dose level 1 (3.3x10^6 cells/kg): two FL patients achieved complete response, WM patient VGPR, HCL-v stable disease with transfusion independence.
- Safety: 3 patients Grade 1 CRS, no ICANS or dose-limiting toxicities; outpatient infusion allowed.
- Patients heavily pre-treated (median 5.5 prior lines); WM patient had nine prior treatments including auto-SCT.
- Pivotal Phase 2 WM trial expected to start mid-2024 with top-line data possible by mid-2026.

## SEC filing metadata
- accession: 0001558370-23-017412
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/0001558370-23-017412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000155837023017412/tmb-20231102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017412
- JSON: https://secwatch.observer/filing/0001558370-23-017412.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.